Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.
After a string of pipeline failures, Vical has called in advisers to help decide the future of the company.
AMPLEXOR Life Sciences: Helping Life Sciences Firms Optimize Routine Document Production
A capsaicin-based therapy developed by University of Wyoming scientists showed promise in mouse models of obesity.
Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.
The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need…
Novartis will take MOR106 forward in atopic dermatitis and other indications, handing over up to €850 million in milestones as it goes.
The deal sees Kite take a stake in Gadeta and commit to milestones tied to the progress of oncology candidates.
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.
A startup from Johns Hopkins launched with $36 million to bring a potentially disease-modifying drug into phase 1 for Parkinson’s disease.
The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.
A new “venture philanthropy” accelerator is offering over $30 million in grants for new biomarkers and diagnostic tests for Alzheimer’s disease.